News Headlines Article

Edison Pharmaceuticals sees hope despite failed rare-disease drug trial
San Francisco Business Times

An Edison Pharmaceuticals Inc. drug focused on a neurological disorder in young girls failed a mid-stage trial, but the Mountain View company still sees promise. EPI-743 failed to lessen the severity of Rett Syndrome, as judged by a subjective score, but the company said girls who received the drug showed a statistically significant increase in head circumference, a key objective measure of the drug’s effectiveness.